ISSUE 91 I FEBRUARY 2020

EDS: treating

a medical zebra

A 'rare' condition that impacts connective tissue may be more common than previously thought, but how is it treated?

Ageing and drug development

Manufacturing drugs in space

Improving access to medicines

In association with

Ageing and drug development

Manufacturing drugs in space

Improving access to medicines

02/24/2024 00:26:53
  • Home | EDS: Treating a medical zebra
  • Scandinavian Health Ltd
  • Editorial
  • Emirates SkyCargo
  • Contents
  • Nolato Company Insight
  • Nolato
  • News
  • The pharma industry briefing
  • Subcuject Company Insight
  • Subcuject
  • Horizon 2020: a look back at flagship EU pharma projects
  • Sanofi
  • Sky high: should US drug prices fall in-line with the rest of the world?
  • Nipro Pharmapackaging
  • Q&A: talking drug quality with Valisure, the first analytical pharmacy
  • Nemera
  • What does ‘ageing’ mean when it comes to drug development?
  • Swiss WorldCargo
  • Manufacturing medicines in space: how astronauts will make their own drugs
  • Mimotopes
  • Aducanumab’s surprising revival: how an Alzheimer’s drug came back from the dead
  • Molnar Company Insight
  • Molnar-Institute
  • Ehlers-Danlos syndrome: The zebra in the room
  • Kugelmeiers
  • Stop ignoring the two billion: pharma’s role in expanding access to medicine
  • Skyepharma
  • IDMP: turning attention to patient benefits
  • Deals in brief powered by GlobalData
  • The key list powered by GlobalData
  • Events
  • Next issue
01/24/2020 00:00:00